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186Background:Management of right ventricular (RV) failure after left ventricular assist device (LVAD) implan-
tation is not evidence based. Temporary circulatory assistance has recently been reported to be of value for man-
aging postoperative RV failure after LVAD implantation, but only in small series of patients or isolated case
reports. We report here our experience with the use of temporary right ventricular assist devices (RVADs) in
LVAD recipients.
Methods: Forty-five of the 488 (9%) patients undergoing LVAD implantation between 2001 and 2011 at the
Clinic for Thoracic and Cardiovascular Surgery in Bad Oeynhausen had RV failure requiring temporary
RVAD. We analyzed preoperative data, complications, mortality at 6 months, and risk factors of death.
Results: The LVAD patients receiving temporary RVAD were younger than the 443 recipients of LVAD alone.
They were more likely to have mechanical ventilation and haemofiltration and their Michigan right ventricular
risk scorewas higher. The LVAD patients with temporary RVAD had a higher mortality at 6 months: 53%, versus
25% for patients receiving LVAD only (P<.001). The univariate risk factors for death were high blood urea
nitrogen and C-reactive protein concentrations, preoperative mechanical ventilation, preoperative hemofiltra-
tion, destination therapy, the use of temporary RVAD, and the development of RV failure. Multivariate analyses
did not identify predictors of death.
Conclusions: The development of RV failure in LVAD recipients is a serious problem associated with high
mortality. Temporary RV mechanical support is an acceptable way to manage postoperative RV failure in these
severely ill LVAD recipients. (J Thorac Cardiovasc Surg 2013;146:186-91)The ventricular assist device (VAD) has become a lifesaving
therapeutic option for patients with end-stage heart failure.1
The occurrence of right ventricular (RV) failure after
implantation of a left ventricular assist device (LVAD) is
associated with significant perioperative mortality and
morbidity.2,3 Many factors contribute to RV failure after
LVAD implantation, complicating the prediction and
management of postoperative RV dysfunction.
Management of RV failure after LVAD implantation is
not evidence-based. Biventricular mechanical support
(BiVAD) is effective but associated with lower survival
and a worse quality of life than left ventricular support
only. The course of BiVAD is complicated by high rates
of major adverse events, such as thromboembolism, device
infections, and mechanical complications.4,5e Heart & Diabetes Center,a North Rhine-Westphalia, Bad Oeynhausen,
any; and the European Georges Pompidou Hospital,b Paris, France.
res: Authors have nothing to disclose with regard to commercial support.
d for publication July 16, 2012; revisions received Dec 20, 2012; accepted for
ation Jan 28, 2013; available ahead of print Feb 25, 2013.
for reprints: Nadia Aissaoui, MD, European Georges Pompidou Hospital,
e Leblanc, 75015 Paris, France (E-mail: nadia.aissaoui@egp.aphp.fr).
23/$36.00
ht  2013 by The American Association for Thoracic Surgery
.doi.org/10.1016/j.jtcvs.2013.01.044
The Journal of Thoracic and Cardiovascular SurgRV failure after LVAD implantation can also be managed
by treating the patient with pulmonary vasodilators and
inotropes, but such drug-based treatment may prove
insufficient.6
The implantation of a temporary RV assist device
(RVAD) has recently been shown to be of value for manag-
ing postoperative RV failure after LVAD implantation.
However, reports to date have been limited to small series
of patients or isolated case reports.7-12
We describe here our experience at Bad Oeynhausen with
the management, by temporary RV mechanical circulatory
support of patients with an LVAD in whom RV failure
develops after surgery.METHODS
Data Collection
Study coordinators, bioengineers, and physicians systematically and
prospectively entered all demographic and clinical data, including all
laboratory test results, adverse events, device-related complications and
malfunctions, and long-term outcomes, into a database at the time of
VAD implantation or registration on the waiting list for transplantation.
This study was carried out in accordance with the Helsinki Declaration;
its database was designed for clinical purposes and for research protocols
approved by the appropriate institutional review board. It was not necessary
to seek informed consent frompatients inasmuch as this observational study
did not modify diagnostic testing or therapeutic interventions.ery c July 2013
Abbreviations and Acronyms
BiVAD ¼ biventricular mechanical support
LVAD ¼ left ventricular assist device
RV ¼ right ventricular
RVAD ¼ right ventricular assist device
VAD ¼ ventricular assist device
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The data were collected prospectively for all patients undergoing VAD
implantation between 2001 and April 2011 at the Clinic for Thoracic and
Cardiovascular Surgery of Bad Oeynhausen (Germany) and were analyzed
retrospectively. During the study period, 488 patients underwent LVAD
implantation. RV failure developed in 77 of these patients, and the
45 patients requiring temporary RVAD were included in our study. All
cases of planned BiVAD were excluded. The BiVAD group comprised
69 patients for whom the decision to implant VAD bilaterally was taken
before surgery and 15 LVAD recipients who could not be weaned from
cardiopulmonary bypass.
Definition and Management of RV Failure
RV failurewas defined as RV dysfunction requiring an RVAD or 14 days
or more of nitrous oxide or inotropic support after LVAD implantation. The
decision to implant an RVAD was made by a heart surgeon in consultation
with a cardiologist specializing in heart failure. This decision was based on
multiple factors, including overall clinical status, patient size, transplant
eligibility, device availability, expected duration of support, and patient
preference.
In all cases, postoperative RV failure in LVAD recipients was initially
managed with drugs: a vasodilator, such as nitroprusside, nitrous oxide,
or iloprost, and an inotrope, such as milrinone, dobutamine, or epinephrine.
If RV function continued to deteriorate and was accompanied by high cen-
tral venous pressure, leading to insufficient loading of the left ventricle, low
output, and a decrease in organ perfusion, a temporary RVAD was im-
planted at the same time or a few days after LVAD implantation in patients
who were expected to be weaned from the RVAD.
Temporary RVAD Implantation
At our center in Bad Oeynhausen, we perform end-to-side anastomosis
with an 8-mm Hemashield graft (St Jude Medical, Inc, St Paul, Minn) and
the pulmonary artery. The graft is tunneled through the skin. The outflow
cannula is inserted over the graft. The inflow cannula is inserted into the
femoral vein, and the Seldinger technique is used to position the cannula
in the right atrium. This method has the advantage that it can be performed
under local anesthesia in the intensive care unit. It is not necessary to open
the chest.
The temporary RVAD was implanted in the perioperative period if
weaning from bypass proved impossible (early RVAD) or after this period
(late RVAD). We divided the group of patients with temporary RVAD into
2 subgroups on the basis of the timing of device insertion: (1) early
temporary RVAD (n ¼ 20) and late temporary RVAD (n ¼ 25). In the
late temporary RVAD subgroup, 17 LVAD recipients underwent temporary
RVAD insertion during the first week after LVAD implantation, and 8 pa-
tients underwent this procedure more than 1 week after LVAD insertion.
Temporary RVAD Management
The temporary RVAD was removed when the patients had no need for
an escalation of inotropic support, low central venous pressure, and an im-
provement of RV systolic function on echocardiography. Echocardiogra-
phy was used to assess the feasibility of RVAD removal. RVAD removalThe Journal of Thoracic and Cawas considered when LVAD flow did not decrease when we reduced
RVAD flow and echocardiographic evaluation showed no RV dilatation.
Patients showing no recovery of RV function after 7 to 14 days were
switched to permanent RVAD or were placed on the list for high emergency
heart transplantation if suitable for this procedure.
Devices
For LVAD recipients with temporary RVAD, we used 9 HeartMate XVE
and 9 HeartMate II devices (Thoratec Corporation, Pleasanton, Calif), 13
HeartWare ventricular assist systems, 5 VentrAssist (Ventracor, Ltd, Chats-
wood, Australia), 5 DuraHeart (Terumo Heart, Inc, Ann Arbor, Mich), and
4 Novacor (Novacor Division of Baxter Healthcare Corp, Oakland, Calif)
devices.
For the other 443 LVAD recipients, we used 50 HeartMate XVE and 111
HeartMate II devices (Thoratec), 75 HeartWare ventricular assist systems
(HeartWare, Inc, Framingham, Mass), 47 VentrAssist devices (Ventracor),
74 DuraHeart devices (Terumo Heart), 53 Novacor devices (Novacor Divi-
sion of Baxter Healthcare Corp), 18 CorAide devices (TheCleveland Clinic
Foundation, Cleveland, Ohio), 9 LionHeart left ventricular assist systems
(Arrow International, Reading, Pa), 4 Incor devices (Berlin Heart AG,
Berlin, Germany), and 2 DeBakey VADs (MicroMed Cardiovascular, Inc,
Houston, Tex).
For short-term RVAD, we initially used 19 Thoratec PVAD devices.
Subsequently, from 2005, we used 26 CentriMag RVADs (Levitronix
LCC,Waltham, Mass) with an extracorporeal magnetically levitated radial
pump.
Patient Characteristics and VAD Implantation
Preoperative data, including demographic and clinical characteristics,
echocardiographic and hemodynamic measurements, laboratory test re-
sults and numbers of inotropes, the day of LVAD implantation and need
for mechanical ventilation, hemofiltration, inotropic drugs, and intra-
arterial balloon pump support were analyzed. The Michigan RV risk score
was calculated for each patient.4 This score assigns points for 4 variables,
with vasopressor use adding 4 points, creatinine concentration of more than
2.3 mg/dL adding 3 points, bilirubin concentration of more than 2 mg/dL
adding 2.5 points, and aspartate aminotransferase levels of more than
80 IU/dL adding 2 points. Higher scores (5.5) are associatedwith a greater
risk of RV failure.
Outcome Data
Complications included acute renal failure, sepsis, adverse cerebral
events, reoperation for bleeding, pump malfunction, and arrhythmia.
Cerebral complications included cerebral hemorrhage, transient ischemia,
and cerebral vascular accident. The dates of device implantation, weaning
from temporary RVAD, and transplantation were recorded. Vital status was
recorded at 6 months and risk factors for death were identified.
Statistical Analysis
The data are expressed as means standard deviation and numbers and
percentages for categorical variables. The Student t test, Mann-Whitney
tests, c2 tests, and Fisher’s exact tests were used for comparisons, as appro-
priate.We compared findings for LVAD recipients with and without tempo-
rary RVAD and according to the time of RVAD implantation. Survival for
the temporary RVAD groups was reported graphically using the Kaplan-
Meier method. A univariate analysis was performed to identify factors
associated with mortality at 6 months. Multivariate analyses of predictors
of death were performed using stepwise multiple logistic regression anal-
ysis. Variables included in the multivariate analyses were selected on their
significance (P<.05) in univariate analyses.
The data were analyzed with the commercially available Statview statis-
tical package, version 5.0 (SAS Institute, Inc, San Francisco, Calif) and
XLSTAT (Addinsoft, Andernach, Germany).rdiovascular Surgery c Volume 146, Number 1 187
TABLE 1. Baseline characteristics of the population
LVAD patients
with temporary
RVAD (N ¼ 45)
LVAD
recipients
(N ¼ 443)
P
value
Age, y 53  14 56  13 .03
Men, n (%) 37 (82) 289 (65) .02
Primary diagnosis n (%)
Ischemic cardiomyopathy 24 (53) 233 (53) NS
Dilated cardiomyopathy 19 (42) 170 (38) NS
Other 2 (5) 40 (9) NS
Intention to treat, n (%)
Bridge to transplantation 35 (78) 309 (70) NS
Destination therapy 10 (22) 115 (26) NS
History of heart surgery, n (%) 18 (40) 138 (31) NS
LV ejection fraction,% 21  6 22  8 NS
Cardiac index, L $ min1 $ m2 2.0  0.5 2.2  0.6 NS
CVP, mm Hg 12  5 11  6 NS
Mean PAP, mm Hg 33  14 31  10 NS
PVR, dynes $ s $ cm5 323  174 249  159 NS
SVR, dynes $ s $ cm5 1194  394 1136  480 NS
PCPW, mm Hg 23  9 20  8 NS
Bilirubin, mg/dL 2.2  0.7 1.6  0.7 <.01
Aspartate aminotransferase, IU/L 159  53 76  23 <.01
BUN, mg/dL 80  28 78  47 NS
Creatinine, mg/L 1.7  0.9 1.6  0.9 NS
CRP, mg/L 7.9  11.6 5.36  6.28 NS
No. of inotropes 2.4  1.2 2.2  0.9 NS
IABP, n (%) 27 (63) 180 (41) .02
Mechanical ventilation, n (%) 15 (34) 80 (18) .01
Hemofiltration, n (%) 16 (38) 79 (18) <.001
Michigan RV risk score 2.9  2.6 1.7  2.5 <.001
Data are expressed as means  standard deviation. LVAD, Left ventricular assist
device; RVAD, right ventricular assist device; LV, left ventricular;CVP, central venous
pressure; PAP, pulmonary artery pressure; PVR, pulmonary vascular resistance;
SVR, systemic vascular resistance; PCWP, pulmonary capillary wedge pressure;
BUN, blood urea nitrogen; CRP, C-reactive protein; IABP, intra-aortic balloon
pump; RV, right ventricular; NS, not significant.
TABLE 2. Adverse events
Adverse events, n (%)
LVAD patients with
temporary RVAD,
N ¼ 45
LVAD patients,
N ¼ 443
Reoperation for bleeding 27 (60) 90 (20)*
Acute renal failure 33 (73) 166 (28)*
Stroke 10 (22) 126 (28)
Cerebral hemorrhage 7 (16) 40 (9)
Transient ischemia 1 (2) 39 (9)
Cerebral vascular accident 2 (4) 47 (11)
Sepsis 16 (36) 160 (36)
Arrythmia 13 (30) 98 (22)
Device malfunction 2 (4) 91(20)*
LVAD, Left ventricular assist device; RVAD, right ventricular assist device. *P<.05
TABLE 3. Risk factors for death
Factors OR for death 95% CI P value
Destination therapy 7.39 4.09-13.4 <.0001
Temporary RVAD 3.43 1.77-6.67 .0001
Postoperative RV failure 2.85 1.68-4.87 <.0001
CRP>2.3 mg/l 2.41 1.59-3.65 <.0001
BUN>62 mg/dl 2.28 1.51-3.45 <.0001
Preoperative hemofiltration 1.82 1.09-3.03 .02
Preoperative MV 1.70 1.00-2.90 .003
OR, Odds ratio; CI, confidence interval; RVAD, right ventricular assist device;
RV, right ventricular;CRP,C-reactive protein;BUN, blood urea nitrogen;MV,mechanical
ventilation.
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MRESULTS
Baseline Characteristics of the LVAD Patients, as
a Function of the Presence or Absence of Temporary
RVAD
The baseline characteristics of the patients are shown in
Table 1. The LVAD patients with temporary RVAD were
younger than those without temporary RVAD. They were
also more likely to have a preoperative intra-aortic balloon
pump, mechanical ventilation, and hemofiltration, and their
Michigan RV risk scores were higher.
Outcome of the Patients as a Function of the Presence
or Absence of Temporary RVAD
The postoperative adverse events observed are reported
in Table 2. The LVAD recipients with temporary RVAD
were more likely to have postoperative bleeding requiring
reoperation and acute renal failure. Mortality at 6 months
was higher for LVAD patients with temporary RVAD than
for those without RVAD: 53% in the LVAD patients with188 The Journal of Thoracic and Cardiovascular Surgtemporary RVAD versus 25% in patients with LVAD only
(P<.001).Risk Factors for Death
The univariate risk factors for death were high blood urea
nitrogen and C-reactive protein concentrations, preopera-
tive mechanical ventilation, preoperative hemofiltration,
destination therapy, the use of temporary RVAD, and the de-
velopment of RV failure (Table 3). Multivariate analyses
did not identify predictors of death.Baseline Characteristics as a Function of the Timing
of RVAD Implantation
Baseline characteristics were similar in LVAD patients
with early temporary RVAD (n ¼ 20) and LVAD patients
with late temporary RVAD (n ¼ 25) (Table 4).Outcome of the Patients as a Function of the Timing
of RVAD Implantation
The median duration of temporary RVAD support was
similar in the 2 groups: 21 days (range, 7-90 days) in the
early temporary RVAD group versus 33 days (range, 12-
147 days) in the late temporary RVAD group (P ¼ .054).
The incidence of complications was also similar in the
2 groups (Table 4). The 6-month Kaplan-Meier actuarial
survival was 50% in the early temporary RVAD groupery c July 2013
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FIGURE 1. Six-month Kaplan-Meier actuarial survivals. RVAD, Right
ventricular assist device.
TABLE 4. Baseline characteristics as a function of the timing of RVAD
implantation
Temporary RVAD
Early RVAD
implantation
(n ¼ 20)
Late RVAD
implantation
(n ¼ 25)
P
value
Age, y 53.5  16.3 51.9  10.8 NS
Men, n (%) 13 (81) 10 (90) NS
Primary diagnosis, n (%)
Ischemic cardiomyopathy 6 (38) 7 (64) NS
Dilated cardiomyopathy 8 (50) 4 (36) NS
Other 2 (12) 0 NS
Intention to treat n (%)
Bridge to transplantation 14 (88) 8 (73) NS
Destination therapy 2 (12) 3 (27) NS
History of heart surgery, n (%) 8 (50) 2 (18) .04
LV ejection fraction,% 19  9 18  4 NS
Cardiac index, L $ min1 $ m2 2.1  0.6 2.1  0.4 NS
CVP, mm Hg 12  6 11  7 NS
Mean PAP, mm Hg 32  10 37  12 NS
PVR, dynes $ s $ cm5 287  192 262  194 NS
SVR, dynes $ s $ cm5 1126  442 1107  330 NS
PCWP, mm Hg 21  7 24  10 NS
Bilirubin, mg/dL 2.8  0.7 1.6  0.6 NS
Aspartate aminotransferase, IU/L 84  58 66  42 NS
BUN, mg/dL 82  46 84  43 NS
Creatinine, mg/L 1.6  0.7 2.0  1.1 NS
CRP, mg/L 6.2  2.9 9.2  15.6 NS
No. of inotropes 2.3  0.8 2.8  1.2 NS
IABP, n (%) 10 (63) 7 (70) NS
Mechanical ventilation, n (%) 5 (31) 4 (40) NS
Hemofiltration, n (%) 4 (27) 3 (30) NS
Michigan RV risk score 3.0  2.4 2.0  1.7 .08
Numeric data are expressed as means  standard deviation. RVAD, Right ventricular
assist device; LV, left ventricular; CVP, central venous pressure; PAP, pulmonary
artery pressure; PVR, pulmonary vascular resistance; SVR, systemic vascular resis-
tance; PCWP, pulmonary capillary wedge pressure; BUN, blood urea nitrogen;
CRP, C-reactive protein; IABP, intra-aortic balloon pump; RV, right ventricular;
NS, not significant.
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Figure 1).
Outcomes are reported in Figure 2.DISCUSSION
We report here the largest ever series of LVAD recipients
with postoperative RV failure managed by temporary
RVAD support (n ¼ 45). The incidence of RV failure after
LVAD in our series was 16%, similar to the values reported
in previous studies.2-4
LVADtreatment in patientswith end-stage heart failure can
exacerbate pre-existing RV failure by increasing preloading,
transiently increasing the pulmonary vascular resistance
related to cardiopulmonary bypass, and decompressing the
left ventricle with septal shift.6 However, the right ventricle
can recover, and this justifies the use of temporary RV me-
chanical support as a strategy for managing RV failure occur-
ring shortly after LVAD implantation.
Weaning from RVAD support was possible in 9 (20%)
patients in this study. This rate is lower than those in previ-
ous studies,8,9,11 which reported RVAD weaning rates ofLate temporary RVAD 
n = 25 
eaning: n = 4 (16%) 
nsplantation: n = 5 (20%) 
tinuation: n = 2 (8%) 
 Mortality at 6 months: n = 14 (56%) 
assist device; VAD, ventricular assist device.
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TABLE 5. Review of studies of temporary RVAD use in LVAD recipients
First author Study period No. of patients Support time Weaning from RVAD Mortality
Dang12 1996-2004 14 13  17* — 9/14 (64%)
Shuhaiber10 2004-2006 5 26.6 (4-51) — 5/5 (100%)
Bhama11 2005-2008 12 8  8* 7/12 (58%) 7/12 (58%)
John9 2009 12 14 (1-29) 6/12 (50%) 8/12 (67%)
Haneya8 2008-2011 8 14 (12-14) 6/8 (75%) 2/8 (25%)
RVAD, Right ventricular assist device; LVAD, left ventricular assist device. *Data are expressed as means  standard deviation or medians with interquartile ranges.
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our strategy. At our center, patients who cannot be weaned
from RVAD are directly placed on the high emergency
list for heart transplantation, provided they have no
contraindication for this procedure. Thus, 8 (17%) of our
patients underwent transplantation. In the other studies, the
patients initially underwent permanent RVAD implantation
to bridge the gap to heart transplantation.9-12 The mean
duration of RVAD support was greater in our study than in
previous studies8-12 owing to this strategy, inasmuch as the
mean time to high emergency transplantation in Germany is
3 months. Despite this longer time on RVAD support, the
frequency of complications was similar to that reported by
Bhama,11 Dang,12 John,9 and their associates.
Mortality at 6 months was also similar to that reported in
previous studies (Table 5). Bhama and associates11 reported
a late mortality of 58% in 12 VAD recipients with tempo-
rary RVAD implants between 2005 and 2008. In a similar
study describing 12 LVAD patients receiving temporary
RVAD, mortality at 6 months was 67%.9 However, 1 study,
conducted by Shuhaiber and colleagues10 on 5 patients, re-
ported a higher mortality (100%) in patients with tempo-
rary RVAD support. In this study, 3 (60%) patients
underwent late implantation, between the 3 and 9 days after
LVAD implantation.10
Recent studies have demonstrated that better results are
obtained with early than with late RVAD implantation. Fitz-
patrick and coworkers13 found, in a study of 99 patients with
permanent BiVAD, that better results were obtained for
planned BiVAD implantation than for late BiVAD implan-
tation. In the study conducted by Morgan and colleagues14
on 17 LVAD recipients requiring RVAD, 7 (70%) of the pa-
tients in the early RVAD implantation group were subse-
quently able to undergo transplantation versus 4 (57.1%)
of the 7 patients who underwent late RVAD implantation
(P< .001). Haneya and associates8 reported their experi-
ences with 8 LVAD patients undergoing temporary RVAD
implantation, 7 of whom underwent the procedure during
the perioperative period. Five (63%) of these patients
were subsequently discharged from the hospital.
We found no difference in the frequency of adverse
events and mortality as a function of the timing of RVAD
implantation in our patients on temporary RVAD support,
probably because of the relatively small number of patients
in this series.190 The Journal of Thoracic and Cardiovascular SurgIn our study, the mortality of LVAD patients requiring
RVAD remained higher than that in patients undergoing
LVAD implantation only. The condition of these patients
was more severe at the time of LVAD implantation. They
were more likely to have intra-aortic balloon pumps, me-
chanical ventilation and hemofiltration, greater impairment
of renal and liver function, and a higher Michigan RV risk
score. The occurrence of RV failure after LVAD implanta-
tion remains a severe complication associated with excess
mortality.
Some univariate risk factors for death were identified, re-
flecting the severity of heart failure in these patients (high
blood urea nitrogen and C-reactive protein concentrations,
preoperative mechanical ventilation, preoperative hemofil-
tration). Destination therapy was also identified as a risk
factor for death. In future trials, it will be important to eval-
uate the predictors of recovery. It is currently difficult to
choose between LVAD with temporary RVAD and primary
BiVAD support. Inasmuch as there is currently no approved
BiVAD device available for destination therapy, only LVAD
can be offered to this population of patients.
In conclusion, the development of RV failure in LVAD
recipients remains a serious problem, associated with high
mortality. Temporary RV mechanical support is an accept-
able approach to the management of postoperative RV
failure in LVAD recipients.References
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